Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the European Institute of Oncology Group

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

High concentrations of subtype 2 somatostatin tumor receptors (sst2) are expressed in numerous tumors, enabling primary and metastatic masses to be localized by scintigraphy after injecting 111In-labeled somatostatin analogue octreotide. In addition to neuroendocrine tumors, somatostatin receptors have been identified on cancers of the central nervous system, breast, lung, and lymphatic tissue, and the use of radionuclide-labeled somatostatin analogues appeared promising for therapy as well as for diagnosis of such malignancies. The somatostatin analogue [DOTA-DPhe1-Tyr3] octreotide (DOTATOC) possesses favorable characteristics for its potential therapeutic use in that it shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3, high hydrophilicity, stable and facile labeling with 111In and 90Y. We began to investigate the potential therapeutic applications of 90Y DOTATOC in 1997 by performing a thorough dosimetric study in 18 patients who were administered 111In DOTATOC to estimate the absorbed doses during 90Y-DOTATOC therapy. Then, we moved on and treated an overall number of 256 patients, mostly recruited in 2 distinct protocols with and without the administration of kidney protecting agents, with 90Y DOTATOC. No major acute reactions were observed up to the activity of 5.55 GBq per cycle, The MTD per cycle was defined as 5.18 GBq. Objective therapeutic responses were documented in more than 20% of patients in terms of partial and complete responses. The present article reports in details our clinical experience (still ongoing) and outcomes with the use of 90Y DOTATOC.

Original languageEnglish
Pages (from-to)141-147
Number of pages7
JournalSeminars in Nuclear Medicine
Volume32
Issue number2
Publication statusPublished - 2002

Fingerprint

Octreotide
Radiotherapy
Somatostatin
Neoplasms
Somatostatin Receptors
Neuroendocrine Tumors
Lymphoid Tissue
Therapeutic Uses
Therapeutics
Hydrophobic and Hydrophilic Interactions
Radioisotopes
Radionuclide Imaging
Breast
Central Nervous System
Kidney
Lung

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

@article{6b11d30995a54ef49c19ccd2be72cfd9,
title = "Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the European Institute of Oncology Group",
abstract = "High concentrations of subtype 2 somatostatin tumor receptors (sst2) are expressed in numerous tumors, enabling primary and metastatic masses to be localized by scintigraphy after injecting 111In-labeled somatostatin analogue octreotide. In addition to neuroendocrine tumors, somatostatin receptors have been identified on cancers of the central nervous system, breast, lung, and lymphatic tissue, and the use of radionuclide-labeled somatostatin analogues appeared promising for therapy as well as for diagnosis of such malignancies. The somatostatin analogue [DOTA-DPhe1-Tyr3] octreotide (DOTATOC) possesses favorable characteristics for its potential therapeutic use in that it shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3, high hydrophilicity, stable and facile labeling with 111In and 90Y. We began to investigate the potential therapeutic applications of 90Y DOTATOC in 1997 by performing a thorough dosimetric study in 18 patients who were administered 111In DOTATOC to estimate the absorbed doses during 90Y-DOTATOC therapy. Then, we moved on and treated an overall number of 256 patients, mostly recruited in 2 distinct protocols with and without the administration of kidney protecting agents, with 90Y DOTATOC. No major acute reactions were observed up to the activity of 5.55 GBq per cycle, The MTD per cycle was defined as 5.18 GBq. Objective therapeutic responses were documented in more than 20{\%} of patients in terms of partial and complete responses. The present article reports in details our clinical experience (still ongoing) and outcomes with the use of 90Y DOTATOC.",
author = "Marco Chinol and Lisa Bodei and Marta Cremonesi and Giovanni Paganelli",
year = "2002",
language = "English",
volume = "32",
pages = "141--147",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide

T2 - The experience of the European Institute of Oncology Group

AU - Chinol, Marco

AU - Bodei, Lisa

AU - Cremonesi, Marta

AU - Paganelli, Giovanni

PY - 2002

Y1 - 2002

N2 - High concentrations of subtype 2 somatostatin tumor receptors (sst2) are expressed in numerous tumors, enabling primary and metastatic masses to be localized by scintigraphy after injecting 111In-labeled somatostatin analogue octreotide. In addition to neuroendocrine tumors, somatostatin receptors have been identified on cancers of the central nervous system, breast, lung, and lymphatic tissue, and the use of radionuclide-labeled somatostatin analogues appeared promising for therapy as well as for diagnosis of such malignancies. The somatostatin analogue [DOTA-DPhe1-Tyr3] octreotide (DOTATOC) possesses favorable characteristics for its potential therapeutic use in that it shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3, high hydrophilicity, stable and facile labeling with 111In and 90Y. We began to investigate the potential therapeutic applications of 90Y DOTATOC in 1997 by performing a thorough dosimetric study in 18 patients who were administered 111In DOTATOC to estimate the absorbed doses during 90Y-DOTATOC therapy. Then, we moved on and treated an overall number of 256 patients, mostly recruited in 2 distinct protocols with and without the administration of kidney protecting agents, with 90Y DOTATOC. No major acute reactions were observed up to the activity of 5.55 GBq per cycle, The MTD per cycle was defined as 5.18 GBq. Objective therapeutic responses were documented in more than 20% of patients in terms of partial and complete responses. The present article reports in details our clinical experience (still ongoing) and outcomes with the use of 90Y DOTATOC.

AB - High concentrations of subtype 2 somatostatin tumor receptors (sst2) are expressed in numerous tumors, enabling primary and metastatic masses to be localized by scintigraphy after injecting 111In-labeled somatostatin analogue octreotide. In addition to neuroendocrine tumors, somatostatin receptors have been identified on cancers of the central nervous system, breast, lung, and lymphatic tissue, and the use of radionuclide-labeled somatostatin analogues appeared promising for therapy as well as for diagnosis of such malignancies. The somatostatin analogue [DOTA-DPhe1-Tyr3] octreotide (DOTATOC) possesses favorable characteristics for its potential therapeutic use in that it shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3, high hydrophilicity, stable and facile labeling with 111In and 90Y. We began to investigate the potential therapeutic applications of 90Y DOTATOC in 1997 by performing a thorough dosimetric study in 18 patients who were administered 111In DOTATOC to estimate the absorbed doses during 90Y-DOTATOC therapy. Then, we moved on and treated an overall number of 256 patients, mostly recruited in 2 distinct protocols with and without the administration of kidney protecting agents, with 90Y DOTATOC. No major acute reactions were observed up to the activity of 5.55 GBq per cycle, The MTD per cycle was defined as 5.18 GBq. Objective therapeutic responses were documented in more than 20% of patients in terms of partial and complete responses. The present article reports in details our clinical experience (still ongoing) and outcomes with the use of 90Y DOTATOC.

UR - http://www.scopus.com/inward/record.url?scp=0036229521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036229521&partnerID=8YFLogxK

M3 - Article

C2 - 11965609

AN - SCOPUS:0036229521

VL - 32

SP - 141

EP - 147

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 2

ER -